Adding ADT to Radiotherapy Improves PFS in Patients With Prostate Cancer

A follow-up analysis of the GETUG-AFU 16 trial demonstrated that adding androgen deprivation therapy (ADT) to radiotherapy salvage treatment reduces clinical progression and death in patients with prostate cancer (Lancet Oncol. 2019 Oct 16. Epub ahead of print).

The follow-up study was done to provide additional data on the efficacy of adding ADT to radiotherapy as salvage treatment after radical prostatectomy for prostate cancer.

“In this follow-up study, we aimed to update the results of the GETUG-AFU 16 trial, which assessed the efficacy of radiotherapy plus androgen suppression versus radiotherapy alone,” explained Christian Carrie, MD, Léon Bérard Center, Lyon, France and colleagues.

A total of 743 patients with prostate cancer were enrolled in the phase 3, randomized trial and randomly assigned to receive radiotherapy (n = 374) or radiotherapy plus goserelin (n = 369) between October 2006 and March 2010.

Patients received 3D conformal radiotherapy or intensity-modulated radiotherapy of 66 Gy in 33 fractions 5 days a week for 7 weeks; those in the radiotherapy plus goserelin arm also received 10.8 mg of goserelin on the first day of irradiation and 3 months later.

The primary end point was PFS in the intent-to-treat population.

The median follow-up at the time of data collection (March 2019) was 112 months. Among patients treated with radiotherapy plus goserelin, the rate of 120-month PFS was 64% (95% CI, 58-69) versus 49% with radiotherapy alone.

“The results of the GETUG-AFU 16 trial confirm the efficacy of androgen suppression plus radiotherapy as salvage treatment in patients with increasing PSA [prostate-specific antigen] concentration after radical prostatectomy for prostate cancer,” Dr Carrie et al concluded.—Kaitlyn Manasterski

Contact Us

(*) Fields Are Mandatory